EBRANTIL

This brand name is authorized in Austria, Croatia, Germany, Japan, Poland, Turkey.

Active ingredients

The drug EBRANTIL contains one active pharmaceutical ingredient (API):

1	Urapidil UNII A78GF17HJS - URAPIDIL
	Urapidil is a α1-adrenoceptor antagonist and 5-HT1A receptor agonist and consequently inhibits the vasoconstrictor effect of catecholamines. It interacts with peripheral α1-adrenoceptors and central 5-HT1A receptors to produce vasodilation without sympathetic activation.
	Read more about Urapidil

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C02CA06	Urapidil	C Cardiovascular system → C02 Antihypertensives → C02C Antiadrenergic agents, peripherally acting → C02CA Alpha-adrenoreceptor antagonists
Discover more medicines within C02CA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00211725, 00212759, 01043603, 01344486, 01344492, 01881356, 01882611, 02192908, 03207948, 03207954, 03207983, 03208008, 03209404, 03209410, 04174091, 05556357, 06064604, 06339403, 06683460, 07745252, 07745269, 09780146, 09780152, 09780169, 09780181
HR	Agencija za lijekove i medicinske proizvode	HR-H-210838878, HR-H-342226756, HR-H-815495516, HR-H-868218212, HR-H-898053873
JP	医薬品医療機器総合機構	2149020N1031, 2149020N2038
PL	Rejestru Produktów Leczniczych	100021016, 100254163
TR	İlaç ve Tıbbi Cihaz Kurumu	8699456790171, 8699456790188